Mirae Asset Global Investments Co. Ltd. Sells 81 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Mirae Asset Global Investments Co. Ltd. lessened its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 7.8% in the 4th quarter, HoldingsChannel.com reports. The fund owned 958 shares of the company’s stock after selling 81 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Krystal Biotech were worth $153,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in KRYS. Segall Bryant & Hamill LLC lifted its holdings in Krystal Biotech by 352.4% in the 3rd quarter. Segall Bryant & Hamill LLC now owns 157,144 shares of the company’s stock worth $28,605,000 after purchasing an additional 122,407 shares during the last quarter. State Street Corp lifted its stake in shares of Krystal Biotech by 9.0% in the third quarter. State Street Corp now owns 1,452,811 shares of the company’s stock worth $264,455,000 after buying an additional 119,936 shares during the last quarter. Franklin Resources Inc. boosted its holdings in shares of Krystal Biotech by 34.2% during the 3rd quarter. Franklin Resources Inc. now owns 243,760 shares of the company’s stock worth $43,774,000 after buying an additional 62,178 shares during the period. Braidwell LP grew its stake in Krystal Biotech by 57.4% in the 3rd quarter. Braidwell LP now owns 168,691 shares of the company’s stock valued at $30,707,000 after buying an additional 61,512 shares during the last quarter. Finally, Edgestream Partners L.P. bought a new position in Krystal Biotech in the 3rd quarter worth $5,872,000. Institutional investors and hedge funds own 86.29% of the company’s stock.

Krystal Biotech Stock Performance

NASDAQ KRYS opened at $155.75 on Friday. Krystal Biotech, Inc. has a twelve month low of $107.50 and a twelve month high of $219.34. The stock has a market cap of $4.48 billion, a PE ratio of 87.99 and a beta of 0.84. The firm has a 50-day simple moving average of $159.73 and a 200 day simple moving average of $176.66.

Insiders Place Their Bets

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction on Friday, December 13th. The shares were sold at an average price of $164.78, for a total value of $4,119,500.00. Following the sale, the insider now owns 1,475,882 shares of the company’s stock, valued at $243,195,835.96. The trade was a 1.67 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 14.10% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. HC Wainwright restated a “buy” rating and set a $221.00 price target on shares of Krystal Biotech in a report on Wednesday, December 18th. Citigroup boosted their price objective on Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $212.00 target price on shares of Krystal Biotech in a report on Wednesday, December 18th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Krystal Biotech presently has a consensus rating of “Buy” and a consensus target price of $206.67.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).